Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
NCT05119296Phase 2Active, not recruiting
- Start
- Feb 2022
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in anaplastic thyroid cancer (ATC), undifferentiated thyroid cancer (ATC). Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
anaplastic thyroid cancer (ATC)undifferentiated thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT05119296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119296.